Updated Phase 1 data for ELVN-001 expected mid-2025 as positive enrollment momentum continues Expected monotherapy and combination data from the ELVN-002 Phase 1 trials ...
Takeda is sharpening its oncology focus amid an R&D revamp. Sun Pharma will acquire Checkpoint Therapeutics and an ...
Investment analysts at HC Wainwright upped their Q1 2025 earnings per share estimates for Zymeworks in a note issued to investors on Monday, March 10th. HC Wainwright analyst R. Burns now anticipates ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results